title: Comparison of the effects of pantethine and fursultiamine on plasma gastrointestinal peptide levels in healthy volunteers.
abstract: Pantethine and fursultiamine have been evaluated for their clinical usefulness in the treatment and prevention of uncomplicated postoperative adhesive intestinal obstruction. In recent years, the actions of drugs used to treat gastrointestinal diseases have been elucidated pharmacologically from the viewpoints of gastrointestinal peptide levels. We examined the effects of pantethine and fursultiamine on plasma levels of calcitonin gene-related peptide (CGRP)-, vasoactive intestinal polypeptide (VIP)-, motilin- and substance P (SP)-like immunoreactive substances (IS) in healthy subjects. An open-labeled study was conducted on five healthy volunteers. Each subject was administered a single oral dose of pantethine, fursultiamine and placebo at intervals of one month. Venous blood samples were collected before and at 20, 40, 60, 90, 120, 180 and 240 min after each administration. Plasma peptide levels were measured using a highly sensitive enzyme immunoassay. A single oral dose of pantethine resulted in significant increases of plasma CGRP- and VIP-IS levels compared to placebo. Furthermore, areas under the plasma concentration-time curves (AUC(0-240)) of CGRP- and VIP-IS were significantly higher after pantethine administration compared with placebo. On the other hand, fursultiamine had no effect on plasma levels and AUC(0-240) of CGRP-, VIP-, motilin- and SP-IS. This study demonstrated the different effects of pantethine and fursultiamine from the viewpoint of plasma gastrointestinal peptide changes. The pharmacological effects of pantethine may be closely related to the changes in plasma CGRP- and VIP-IS levels.
authors.affiliation: Department of Clinical Pharmacy, Oita University Hospital, Japan. y-suzuki@oita-u.ac.jp
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Hiroki
authors.initials: H
authors.lastname: Itoh
authors.forename: Tomohide
authors.initials: T
authors.lastname: Abe
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Nishimura
authors.forename: Yuhki
authors.initials: Y
authors.lastname: Sato
authors.forename: Masaharu
authors.initials: M
authors.lastname: Takeyama
mesh_terms: D000328:Adult; D015740:Calcitonin Gene-Related Peptide / Q000097:blood / Q000187:drug effects / Q000378:metabolism*; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D005666:Fursultiamin / Q000494:pharmacology*; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D009037:Motilin / Q000097:blood / Q000187:drug effects / Q000378:metabolism*; D010204:Pantetheine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013373:Substance P / Q000097:blood / Q000187:drug effects / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000097:blood / Q000187:drug effects / Q000378:metabolism*; D014803:Vitamin B Complex / Q000494:pharmacology*
chemical_list: D005666:Fursultiamin; D014803:Vitamin B Complex; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D010204:Pantetheine; D009037:Motilin; C005425:pantethine; D015740:Calcitonin Gene-Related Peptide